📊 CELG-RI Key Takeaways
Investment Thesis
Bristol Myers Squibb demonstrates solid fundamental health with strong profitability margins (63.8% gross, 14.6% net) and exceptional cash generation (FCF of $12.8B, 26.7% margin). However, revenue stagnation (-0.2% YoY) and elevated leverage (2.43x debt-to-equity) warrant caution, despite manageable interest coverage of 21.9x and strong operational efficiency metrics.
CELG-RI Strengths
- Exceptional free cash flow generation of $12.8B with 26.7% FCF margin indicating robust operational cash conversion
- Strong profitability with gross margin of 63.8% and net margin of 14.6%, reflecting pricing power and cost discipline
- Excellent interest coverage ratio of 21.9x demonstrates comfortable debt servicing capacity despite high absolute debt levels
- High return on equity of 38.2% indicates efficient capital deployment in shareholder value creation
CELG-RI Risks
- Revenue stagnation with flat year-over-year growth (-0.2%) suggests mature portfolio without clear growth catalysts
- Elevated leverage with debt-to-equity ratio of 2.43x and $44.8B long-term debt; vulnerable to rising interest rates
- Modest current ratio of 1.26x indicates tightened short-term liquidity relative to current liabilities
- Pharmaceutical industry exposure to patent expirations, pricing pressures, and regulatory headwinds
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Debt reduction progress and leverage ratio improvement toward healthier 2.0x threshold
- Free cash flow sustainability and maintenance of 25%+ FCF margins
- Operating margin stability amid pricing and cost pressures in pharma sector
CELG-RI Financial Metrics
💡 AI Analyst Insight
The 26.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
CELG-RI Profitability Ratios
CELG-RI vs Healthcare Sector
How BRISTOL MYERS SQUIBB CO compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CELG-RI Balance Sheet & Liquidity
CELG-RI 5-Year Financial Trend
5-Year Trend Summary: BRISTOL MYERS SQUIBB CO's revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $3.86 reflects profitable operations.
CELG-RI Growth Metrics (YoY)
CELG-RI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.9B | $1.2B | $0.60 |
| Q2 2025 | $12.2B | $1.3B | $0.64 |
| Q1 2025 | $11.2B | $2.5B | $1.20 |
| Q3 2024 | $11.0B | $1.2B | $0.60 |
| Q2 2024 | $11.2B | $1.7B | $0.83 |
| Q1 2024 | $11.3B | $2.3B | $1.07 |
| Q3 2023 | $11.0B | $1.6B | $0.75 |
| Q2 2023 | $11.2B | $1.4B | $0.66 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CELG-RI Capital Allocation
CELG-RI SEC Filings
Access official SEC EDGAR filings for BRISTOL MYERS SQUIBB CO (CIK: 0000014272)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773347083.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773347025.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773346981.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773346920.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773346864.xml | View → |
❓ Frequently Asked Questions about CELG-RI
What is the AI rating for CELG-RI?
BRISTOL MYERS SQUIBB CO (CELG-RI) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELG-RI's key strengths?
Exceptional free cash flow generation of $12.8B with 26.7% FCF margin indicating robust operational cash conversion. Strong profitability with gross margin of 63.8% and net margin of 14.6%, reflecting pricing power and cost discipline.
What are the risks of investing in CELG-RI?
Revenue stagnation with flat year-over-year growth (-0.2%) suggests mature portfolio without clear growth catalysts. Elevated leverage with debt-to-equity ratio of 2.43x and $44.8B long-term debt; vulnerable to rising interest rates.
What is CELG-RI's revenue and growth?
BRISTOL MYERS SQUIBB CO reported revenue of $48.2B.
Does CELG-RI pay dividends?
BRISTOL MYERS SQUIBB CO pays dividends, with $5,045.0M distributed to shareholders in the trailing twelve months.
Where can I find CELG-RI SEC filings?
Official SEC filings for BRISTOL MYERS SQUIBB CO (CIK: 0000014272) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELG-RI's EPS?
BRISTOL MYERS SQUIBB CO has a diluted EPS of $3.46.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.